Shares of Merck KGaA (OTCMKTS:MKKGY – Get Free Report) have earned an average rating of “Hold” from the six research firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Several research firms recently commented on MKKGY. Zacks Research upgraded shares of Merck KGaA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 22nd. HSBC upgraded shares of Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Finally, Jefferies Financial Group assumed coverage on shares of Merck KGaA in a research report on Tuesday, May 26th. They set a “hold” rating on the stock.
Get Our Latest Stock Analysis on MKKGY
Merck KGaA Stock Performance
Merck KGaA (OTCMKTS:MKKGY – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.14. Merck KGaA had a return on equity of 8.79% and a net margin of 12.07%.The firm had revenue of $6.03 billion for the quarter, compared to analyst estimates of $5.93 billion. Research analysts anticipate that Merck KGaA will post 1.87 earnings per share for the current year.
Merck KGaA Company Profile
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
Featured Stories
- Five stocks we like better than Merck KGaA
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
